Q-omics provides the consensus-scored CCNG1P1 profile across patient tissues and cancer cell-line models. CCNG1P1 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CCNG1P1 is differentially expressed in 2, with the highest sampling consensus in LIHC. Additionally, CCNG1P1 RNA expression shows 8,309 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight KIRC, LIHC, and LAML as cancer lineages where CCNG1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCNG1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCNG1P1 survival associations across molecular data types. CCNG1P1 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCNG1P1 RNA expression–survival associations across cancer types. High CCNG1P1 expression shows unfavorable associations in LUSC, KIRP, ESCA, BRCA and LAML, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .009). Together, the overview and detailed table identify KIRC as the clearest survival context for CCNG1P1 RNA expression.
This table summarizes CCNG1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for CCNG1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCNG1P1 shows lower tumor expression in LIHC and higher tumor expression in KIRC. The LIHC box plot shows higher CCNG1P1 RNA expression in normal versus tumor tissue (log2 FC = −0.034, t-test p = .031).
This table shows molecular features associated with CCNG1P1 in patient tissues and cancer cell lines. In patient samples, CCNG1P1 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
